tetano
Editor, Senior Moderator
J Med Virol
. 2024 Jun;96(6):e29710.
doi: 10.1002/jmv.29710. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine
Cinzia Borgogna[SUP] 1 [/SUP], Daniela Ferrante[SUP] 2 [/SUP], Greta Rosso[SUP] 3 [/SUP], Gabriele Guglielmetti[SUP] 3 [/SUP], Irene Lo Cigno[SUP] 1 [/SUP], Stefano Raviola[SUP] 1 4 [/SUP], Valeria Caneparo[SUP] 4 [/SUP], Marco Quaglia[SUP] 5 [/SUP], Vincenzo Cantaluppi[SUP] 3 [/SUP], Marisa Gariglio[SUP] 1 [/SUP]
Affiliations
Kidney transplant recipients (KTRs), like other solid organ transplant recipients display a suboptimal response to mRNA vaccines, with only about half achieving seroconversion after two doses. However, the effectiveness of a booster dose, particularly in generating neutralizing antibodies (NAbs), remains poorly understood, as most studies have mainly focused on non-neutralizing antibodies. Here, we have longitudinally assessed the humoral response to the SARS-CoV-2 mRNA vaccine in 40 KTRs over a year, examining changes in both anti-spike IgG and NAbs following a booster dose administered about 5 months post-second dose. We found a significant humoral response increase 5 months post-booster, a stark contrast to the attenuated response observed after the second dose. Of note, nearly a quarter of participants did not achieve protective plasma levels even after the booster dose. We also found that the higher estimated glomerular filtration rate (eGFR) correlated with a more robust humoral response postvaccination. Altogether, these findings underscore the effectiveness of the booster dose in enhancing durable humoral immunity in KTRs, as evidenced by the protective level of NAbs found in 65% of the patients 5 months post- booster, especially those with higher eGFR rates.
Keywords: SARS‐CoV‐2; booster vaccination; estimated glomerular filtration rate (eGFR); kidney transplant recipients (KTRs); neutralizing antibodies.
. 2024 Jun;96(6):e29710.
doi: 10.1002/jmv.29710. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine
Cinzia Borgogna[SUP] 1 [/SUP], Daniela Ferrante[SUP] 2 [/SUP], Greta Rosso[SUP] 3 [/SUP], Gabriele Guglielmetti[SUP] 3 [/SUP], Irene Lo Cigno[SUP] 1 [/SUP], Stefano Raviola[SUP] 1 4 [/SUP], Valeria Caneparo[SUP] 4 [/SUP], Marco Quaglia[SUP] 5 [/SUP], Vincenzo Cantaluppi[SUP] 3 [/SUP], Marisa Gariglio[SUP] 1 [/SUP]
Affiliations
- PMID: 38804187
- DOI: 10.1002/jmv.29710
Kidney transplant recipients (KTRs), like other solid organ transplant recipients display a suboptimal response to mRNA vaccines, with only about half achieving seroconversion after two doses. However, the effectiveness of a booster dose, particularly in generating neutralizing antibodies (NAbs), remains poorly understood, as most studies have mainly focused on non-neutralizing antibodies. Here, we have longitudinally assessed the humoral response to the SARS-CoV-2 mRNA vaccine in 40 KTRs over a year, examining changes in both anti-spike IgG and NAbs following a booster dose administered about 5 months post-second dose. We found a significant humoral response increase 5 months post-booster, a stark contrast to the attenuated response observed after the second dose. Of note, nearly a quarter of participants did not achieve protective plasma levels even after the booster dose. We also found that the higher estimated glomerular filtration rate (eGFR) correlated with a more robust humoral response postvaccination. Altogether, these findings underscore the effectiveness of the booster dose in enhancing durable humoral immunity in KTRs, as evidenced by the protective level of NAbs found in 65% of the patients 5 months post- booster, especially those with higher eGFR rates.
Keywords: SARS‐CoV‐2; booster vaccination; estimated glomerular filtration rate (eGFR); kidney transplant recipients (KTRs); neutralizing antibodies.